rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
1999-6-15
|
pubmed:abstractText |
Treatment of Hodgkin's disease in children should be directed at maximizing cures and minimizing the long-term effects of alkylating agents, anthracyclines, and bleomycin. In this study methotrexate and etoposide were used in the VAMP/VEPA regimens to treat 60 clinically staged pediatric patients with Hodgkin's disease. Twenty-nine patients with stages I-IIA received four courses of VAMP plus low-dose radiotherapy. Thirty-one IIA bulky disease and IIB-IVB patients received four or six courses of VEPA plus low-dose radiotherapy. There were 6 partial remissions after the completion of chemotherapy and all of these patients relapsed, but 4 were successfully salvaged with ABMT. Two patients have died. The 3.1-year overall survival rate is 97% (100% VAMP, 94% VEPA) and the event-free survival rate is 88% (97% VAMP, 77% VEPA). These results suggest that VAMP is a reasonable treatment for low stages of Hodgkin's disease, but more advanced disease is not adequately treated by VEPA and low-dose radiotherapy.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0888-0018
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
141-8
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:10100274-Adolescent,
pubmed-meshheading:10100274-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10100274-Child,
pubmed-meshheading:10100274-Child, Preschool,
pubmed-meshheading:10100274-Combined Modality Therapy,
pubmed-meshheading:10100274-Cyclophosphamide,
pubmed-meshheading:10100274-Disease-Free Survival,
pubmed-meshheading:10100274-Dose-Response Relationship, Radiation,
pubmed-meshheading:10100274-Doxorubicin,
pubmed-meshheading:10100274-Female,
pubmed-meshheading:10100274-Hodgkin Disease,
pubmed-meshheading:10100274-Humans,
pubmed-meshheading:10100274-Male,
pubmed-meshheading:10100274-Methotrexate,
pubmed-meshheading:10100274-Prednisolone,
pubmed-meshheading:10100274-Procarbazine,
pubmed-meshheading:10100274-Retrospective Studies,
pubmed-meshheading:10100274-Survival Rate,
pubmed-meshheading:10100274-Vincristine
|
pubmed:articleTitle |
Treatment of Hodgkin's disease in children with VAMP (vinblastine, adriamycin, methotrexate, prednisone) and VEPA (vinblastine, etoposide, prednisone, adriamycin).
|
pubmed:affiliation |
Department of Pediatric Oncology, Charles University Hospital Motol, Prague, Czech Republic. petr.kavan@lfmotol.cuni.cz
|
pubmed:publicationType |
Journal Article
|